摘要目的:探讨经直肠多模态超声及血清前列腺特异抗原（PSA）预测临床局限性前列腺癌的价值。方法:本研究为横断面研究，采用2014年5月至2020年4月山西医科大学第一医院收治的可疑前列腺结节患者的临床资料，选取其中经临床及病理证实的48例临床局限性前列腺癌和51例前列腺增生为研究对象，比较两组间多模态超声特征，结合PSA，运用logistic逐步回归分析筛选出有统计学意义的指标，建立诊断模型，比较进入方程中的变量优势比（ OR值），绘制受试者工作特征（ROC）曲线，评价诊断模型的预测能力。 结果:logistic回归分析共筛选出4个特征变量，包括增强类型、增强程度、弹性成像模式及PSA。增强程度的 OR值高于其他自变量。诊断模型ROC曲线下面积为0.868（ P<0.01），界值为0.514，预测临床局限性前列腺癌的灵敏度为79.2%，特异度为80.4%。 结论:经直肠多模态超声与血清 PSA 联合诊断模型对预测临床局限性前列腺癌有一定临床应用价值。

abstractsObjective:To explore the predictive value of transrectal multimodal ultrasound and prostate specific antigen (PSA) in clinically organ-confined prostate cancer.Methods:It was a cross-sectional study. The clinical data of patients with suspected prostate nodules treated in the First Hospital of Shanxi Medical University from May 2014 to April 2020 were analyzed retrospectively. Of the patients, 48 cases of clinically organ-confined prostate cancer and 51 cases of benign prostatic hyperplasia confirmed by clinical data and pathology were selected as research objects. The characteristics of transrectal multimodal ultrasound in the two groups were compared. Combined with PSA, logistic regression analysis was applied to screen the statistically significant features, and then the diagnosis model was established, and odds ratio of the variables were compared. The receiver operating characteristic (ROC) curve was constructed to analyze the predicting ability of the diagnosis model.Results:Four features were obtained with logistic regression analysis finally, including enhancement type, enhancement degree, elastography mode and PSA. The odds ratio of enhancement degree was higher than those of the other independent variables. The area under ROC curve of the diagnosis model was 0.868 ( P<0.01), the cut-off value was 0.514. The sensitivity and specificity of the diagnosis model in predicting clinically organ-confined prostate cancer was 79.2% and 80.4%, respectively. Conclusions:This combined diagnosis model of transrectal multimodal ultrasound and PSA has a certain clinical value in predicting clinically organ-confined prostate cancer.